Smouldering malignant melanoma and metastatic dormancy: An update and review

Dermatology Research and Practice

Volumn 2012, Issue , 2012, Pages

  Piérard, Gérald E ^a   Piérard Franchimont, Claudine ^a   Reginster, Marie Annick ^a   Quatresooz, Pascale ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; CANCER STEM CELL; CELL HETEROGENEITY; CELL PROLIFERATION; HOST RESISTANCE; HUMAN; MELANOMA; METASTASIS; PHENOTYPE; REVIEW; SENTINEL LYMPH NODE;

EID: 84874915661     PISSN: None     EISSN: 16876113     Source Type: Journal    
DOI: 10.1155/2012/461278     Document Type: Review

References (46)

1. Clark W. H., Tumour progression and the nature of cancer. British Journal of Cancer 1991 64 4 631 644 2-s2.0-0025909122
2. Elder D. E., Van Belle P., Elenitsas R., Halpern A., Guerry D., Neoplastic progression and prognosis in melanoma. Seminars in Cutaneous Medicine and Surgery 1996 15 4 336 348 2-s2.0-0030425747 (Pubitemid 27197972)
3. Quatresooz P., Piérard-Franchimont C., Paquet P., Piérard G. E., Angiogenic fast-growing melanomas and their micrometastases. European Journal of Dermatology 2010 20 3 302 307 2-s2.0-77952872508 10.1684/ejd.2010. 0929
4. Attis M. G., Vollmer R. T., Mitotic rate in melanoma: a reexamination. American Journal of Clinical Pathology 2007 127 3 380 384 2-s2.0-34247881910 10.1309/LB7RTC61B7LC6HJ6 (Pubitemid 46806331)
5. Balch C. M., Gershenwald J. E., Soong S. J., Thompson J. F., Atkins M. B., Byrd D. R., Buzaid A. C., Cochran A. J., Coit D. G., Ding S., Eggermont A. M., Flaherty K. T., Gimotty P. A., Kirkwood J. M., McMasters K. M., Mihm M. C., Morton D. L., Ross M. I., Sober A. J., Sondak V. K., Final version of 2009 AJCC melanoma staging and classification. Journal of Clinical Oncology 2009 27 36 6199 6206 2-s2.0-74949143594 10.1200/JCO.2009.23.4799
6. Piérard G. E., Piérard-Franchimont C., Henry C., Lapière M., The proliferative activity of cells of malignant melanomas. The American Journal of Dermatopathology 1984 6 1 S317 S323 2-s2.0-0021747706
7. Böni R., Doguoglu A., Burg G., Mûller B., Dummer R., MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. Journal of the American Academy of Dermatology 1996 35 3 416 468 2-s2.0-0029775064
8. Frahm S. O., Schubert C., Parwaresch R., Rudolph P., High proliferative activity may predict early metastasis of thin melanomas. Human Pathology 2001 32 12 1376 1381 2-s2.0-0035677699 10.1053/hupa.2001.29658 (Pubitemid 34038673)
9. Plaza J. A., Suster D., Perez-Montiel D., Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique. Applied Immunohistochemistry and Molecular Morphology 2007 15 4 421 425 2-s2.0-37349081263 10.1097/PAI.0b013e318032ea5d (Pubitemid 350307848)
10. Quatresooz P., Piérard G. E., Piérard-Franchimont C., Mosan Study Grop of Pigmented Tumors, Molecular pathways supporting the proliferation staging of malignant melanoma. International Journal of Molecular Medicine 2009 24 3 295 301 10.3892/ijmm-00000232
11. Quatresooz P., Piérard G. E., Malignant melanoma: from cell kinetics to micrometastases. American Journal of Clinical Dermatology 2011 12 2 77 86 10.2165/11318380-000000000-00000
12. Quatresooz P., Arrese J. E., Piérard-Franchimont C., Piérard G. E., Immunohistochemical aid at risk stratification of melanocytic neoplasms. International Journal of Oncology 2004 24 1 211 216 2-s2.0-3843107068
13. Holmgren L., O'Reilly M. S., Folkman J., Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine 1995 1 2 149 153 2-s2.0-0028951043
14. Piérard G. E., Piérard-Franchimont C., Stochastic relationship between the growth fraction and vascularity of thin malignant melanomas. European Journal of Cancer 1997 33 11 1888 1892 2-s2.0-0344301855 10.1016/S0959-8049(97)00231-1 (Pubitemid 28129222)
15. Piérard-Franchimont C., Henry F., Heymans O., Piérard G. E., Vascular retardation in dormant growth-stunted malignant melanomas. International Journal of Molecular Medicine 1999 4 4 403 406 2-s2.0-0033208648
16. Mikesh L. M., Kumar M., Erdag G., Hogan K. T., Molhoek K. R., Mayo M. W., Slingluff C. L., Evaluation of molecular markers of mesenchymal phenotype in melanoma. Melanoma Research 2010 20 6 485 495 2-s2.0-78349312817 10.1097/CMR.0b013e32833fafb4
17. Quatresooz P., Reginster M. -A., Piérard G. E., The "Malignant melanoma microecosystem": immunohistopathological insights into the stromal cell phenotype: a review. Experimental and Therapeutic Medicine 2011 2 3 379 384 10.3892/etm.2011.221
18. Fang D., Nguyen T. K., Leishear K., Finko R., Kulp A. N., Hotz S., Van Belle P. A., Xu X., Elder D. E., Herlyn M., A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Research 2005 65 20 9328 9337 2-s2.0-27144557960 10.1158/0008-5472.CAN-05-1343 (Pubitemid 41508000)
19. Grichnik J. M., Burch J. A., Schulteis R. D., Shan S., Liu J., Darrow T. L., Vervaert C. E., Seigler H. F., Melanoma, a tumor based on a mutant stem cell? Journal of Investigative Dermatology 2006 126 1 142 153 2-s2.0-33644787015 10.1038/sj.jid.5700017 (Pubitemid 43336106)
20. Klein W. M., Wu B. P., Zhao S., Wu H., Klein-Szanto A. J. P., Tahan S. R., Increased expression of stem cell markers in malignant melanoma. Modern Pathology 2007 20 1 102 107 2-s2.0-33845702260 10.1038/modpathol.3800720 (Pubitemid 44967955)
21. Monzani E., Facchetti F., Galmozzi E., Corsini E., Benetti A., Cavazzin C., Gritti A., Piccinini A., Porro D., Santinami M., Invernici G., Parati E., Alessandri G., La Porta C. A. M., Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. European Journal of Cancer 2007 43 5 935 946 2-s2.0-33847639310 10.1016/j.ejca.2007.01.017 (Pubitemid 46366698)
22. Piérard G. E., Quatresooz P., Rorive A., Piérard- Franchimont C., Mosan Study Group of Pigmented Tumors, Malignant melanoma: conceptual and therapeutic innovations based on translational research. Revue Médicale de Liège 2008 63 10 579 584
23. Henry C., Lapière M., Franchimont C., Piérard G. E., Lapière C. M., Ackerman A. B., Immunotherapy by dinitrochlorobenzene of melanomas of the skin: I- methods, clinical effects and survival rates. Pathology of Malignant Melanoma 1981 New York, NY, USA Pub Masson 367 371
24. Wang E., Voiculescu S. S., Le Poole I. C., El-Gamil M., Li X., Sabatino M., Robbins P. F., Nickoloff B. J., Marincola F. M., Clonal persistence and evolution during a decade of recurrent melanoma. Journal of Investigative Dermatology 2006 126 6 1372 1377 2-s2.0-33745517244 10.1038/sj.jid.5700193 (Pubitemid 43997921)
25. Strauss D. C., Thomas J. M., Transmission of donor melanoma by organ transplantation. The Lancet Oncology 2010 11 8 790 796 2-s2.0-77955268790 10.1016/S1470-2045(10)70024-3
26. Bodenham D. C., A study of 650 observed malignant melanomas in the South-West region. Annals of the Royal College of Surgeons of England 1968 43 4 218 239 2-s2.0-0014337912
27. Harrist T. J., Rigel D. S., Day C. L., Microscopic satellites are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer 1984 53 10 2183 2187 (Pubitemid 14101792)
28. Leon P., Daly J. M., Synnestvedt M., Schultz D. J., Elder D. E., Clark W. H., The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Archives of Surgery 1991 126 12 1461 1468 2-s2.0-0026318663
29. Claessens N., Piérard G. E., Piérard-Franchimont C., Arrese J. E., Quatresooz P., Immunohistochemical detection of incipient melanoma micrometastases: relationship with sentinel lymph node involvement. Melanoma Research 2005 15 2 107 110 2-s2.0-18344369398 10.1097/00008390-200504000-00004 (Pubitemid 40637988)
30. Shaikh L., Sagebiel R. W., Ferreira C. M. M., Nosrati M., Miller J. R., Kashani-Sabet M., The role of microsatellites as a prognostic factor in primary malignant melanoma. Archives of Dermatology 2005 141 6 739 742 2-s2.0-21844432408 10.1001/archderm.141.6.739 (Pubitemid 41001074)
31. Piérard G. E., Henry C., Franchimont C., Lapière M., Ackerman A. B., Lapière C. M., Ackerman A. B., Immunotherapy by dinitrochlorobenzene of melanomas of the skin: II. Histology of the cytotoxic effect. Pathology of Malignant Melanoma 1981 New York, NY, USA Pub Masson 373 385
32. Moreno A., Espanol I., Romagosa V., Angiotropic malignant melanoma: report of two cases. Journal of Cutaneous Pathology 1992 19 4 325 329 2-s2.0-0026788295
33. Shea C. R., Kline M. A., Lugo J., McNutt N. S., Angiotropic metastatic malignant melanoma. The American Journal of Dermatopathology 1995 17 1 58 62 2-s2.0-0028890406
34. Saluja A., Money N., Zivony D. I., Solomon A. R., Angiotropic malignant melanoma: a rare pattern of local metastases. Journal of the American Academy of Dermatology 2001 44 5 829 832 2-s2.0-0035032089 10.1067/mjd.2001.114579 (Pubitemid 32391172)
35. Barnhill R. L., Reinhold U., Tilgen W., The biology of melanoma micrometastases. Minimal Residual Disease in Melanoma: Biology, Detection and Clinical Relevance 2001 Berlin, Germany Springer 3 13
36. Siegel D. M., McClain S. A., Angiotropic malignant melanoma: more common than we think? Journal of the American Academy of Dermatology 2001 44 5 870 871 2-s2.0-0035035743 10.1067/mjd.2001.114578 (Pubitemid 32391181)
37. Barnhill R., Dy K., Lugassy C., Angiotropism in cutaneous melanoma: a prognostic factor strongly predicting risk for metastasis. Journal of Investigative Dermatology 2002 119 3 705 706 2-s2.0-0036381821 10.1046/j.1523-1747.2002.01871.x
38. Barnhill R. L., Lugassy C., Angiotropic malignant melanoma and extravascular migratory metastasis: description of 36 with emphasis on a new mechanism of tumour spread. Pathology 2004 36 5 485 490 2-s2.0-4644242490 10.1080/00313020412331282708 (Pubitemid 39273994)
39. Lugassy C., Barnhill R. L., Angiotropic melanoma and extravascular migratory metastasis: a review. Advances in Anatomic Pathology 2007 14 3 195 201 2-s2.0-34247497633 10.1097/PAP.0b013e31805048d9 (Pubitemid 46659190)
40. Mantovani A., Molecular pathways linking inflammation and cancer. Current Molecular Medicine 2010 10 4 369 373 2-s2.0-77953485565 10.2174/ 156652410791316968
41. Sleeman J. P., Nazarenko I., Thiele W., Do all roads lead to Rome? Routes to metastasis development. International Journal of Cancer 2011 128 11 2511 2526 10.1002/ijc.26027
42. Klein C. A., Framework models of tumor dormancy from patient-derived observations. Current Opinion in Genetics and Development 2011 21 1 42 49 2-s2.0-78649733471 10.1016/j.gde.2010.10.011
43. Goss P. E., Chambers A. F., Does tumour dormancy offer a therapeutic target? Nature Reviews Cancer 2010 10 12 871 877 2-s2.0-78649467513 10.1038/nrc2933
44. Yang Z. J., Chee C. E., Huang S., Sinicrope F. A., Autophagy modulation for cancer therapy. Cancer Biology and Therapy 2011 11 2 169 176 10.4161/cbt.11.2.14663
45. Röcken M., Early tumor dissemination, but late metastasis: insights into tumor dormancy. Journal of Clinical Investigation 2010 120 6 1800 1803 2-s2.0-77953221417 10.1172/JCI43424
46. Eyles J., Puaux A. L., Wang X., Toh B., Prakash C., Hong M., Tan T. G., Zheng L., Ong L. C., Jin Y., Kato M., Prévost-Blondel A., Chow P., Yang H., Abastado J. P., Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. Journal of Clinical Investigation 2010 120 6 2030 2039 2-s2.0-77953225810 10.1172/JCI42002